Table 2.
Transpulmonary thermodilution parameters over the study period
| BASE1 | DOBU | BASE2 | HYPO | BASE3 | HYPER | ALI | |
|---|---|---|---|---|---|---|---|
| CO1 (l/min) | 7.5 ± 0.9, 7.6 (6.9 to 8.2) | 10.8 ± 1.4*, 10.9 (10.0 to 11.5) | 7.5 ± 0.7, 7.4 (7.2 to 7.8) | 4.7 ± 0.3*, 4.9 (4.5 to 4.9) | 7.9 ± 1.2, 7.7 (7.2 to 8.6) | 11.7 ± 2.1*, 11.8 (10.1 to 13.1) | 6.7 ± 3.3*, 5.2 (4.5 to 8.7) |
| CO2 (l/min) | 7.6 ± 0.8, 7.9 (7.3 to 8.1) | 11.0 ± 1.6*, 11.0 (10.1 to 11.7) | 7.6 ± 0.8, 7.3 (7.1 to 8.1) | 4.8 ± 0.2*, 4.9 (4.6 to 4.9) | 8.0 ± 1.2, 8.0 (7.3 to 8.7) | 12.0 ± 2.1*, 11.8 (10.5 to 13.5) | 6.9 ± 3.4*, 5.7 (4.6 to 9.0) |
| GEDV1 (ml) | 1,077 ± 149, 1,116 (953 to 1,171) | 1,059 ± 134, 1,001 (958 to 1,167) | 1,110 ± 147, 1,139 (990 to 1,230) | 925 ± 84*, 943 (885 to 977) | 1,173 ± 120, 1,164 (1,102 to 1,240) | 1,326 ± 140*, 1,288 (1,245 to 1,440) | 1,070 ± 191*, 1,144 (929 to 1,170) |
| GEDV2 (ml) | 1,052 ± 94, 1,040 (1,009 to 1,076) | 1,023 ± 102, 1,038 (942 to 1,056) | 1,093 ± 124, 1,117 (1,000 to 1,177) | 931 ± 66*, 937 (911 to 978) | 1,153 ± 100, 1,157 (1089 to 1,214) | 1,299 ± 162*, 1,322 (1,218 to 1,363) | 1,089 ± 174*, 1,118 (976 to 1,194) |
| EVLW1 (ml) | 622 ± 86, 627 (558 to 684) | 691 ± 112, 650 (631 to 723)** | 653 ± 106, 639 (577 to 692) | 609 ± 72*, 597 (549 to 675) | 644 ± 82, 638 (563 to 710) | 754 ± 117, 804 (654 to 858)** | 1,587 ± 380, 1,609 (1,305 to 1,711)** |
| EVLW2 (ml) | 621 ± 82, 613 (552 to 683) | 642 ± 68, 628 (596 to 666) | 635 ± 85, 619 (592 to 678) | 624 ± 68, 626 (580 to 679) | 624 ± 80, 587 (567 to 710) | 749 ± 128*, 750 (654 to 823) | 1,571 ± 335*, 1,580 (1,374 to 1,752) |
Results are expressed as the mean ± standard deviation, median (interquartile range). CO, cardiac output; GEDV, global end-diastolic volume; EVLW, extravascular lung water; subscript 1, current method (PiCCO™; Pulsion); subscript 2, new method (VolumeView™; Edwards); BASE, baseline; DOBU, dobutamine infusion; HYPO, hypovolemia induced by bleeding; HYPER, hypervolemia induced by volume loading; ALI, acute lung injury induced by oleic acid. *P < 0.01 (DOBU vs. BASE1 or HYPO vs. BASE2 or HYPER vs. BASE3 or ALI vs. HYPER); normal distribution, paired t test. **P < 0.01 (DOBU vs. BASE1 or HYPER vs. BASE3 or ALI vs. HYPER); abnormal distribution, nonparametric paired Wilcoxon signed-rank test. At each stage, values measured with the new VolumeView™ and with the current PiCCO™ method were comparable.